#	Pagina
attuale pagina	/open-h2020/projects/196832/index.html

Opendata, web and dolomites

VIRION SIGNED

Viruses, Immune stimulation and RNA Interference in Oncology Network

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

VIRION project word cloud

Explore the words cloud of the VIRION project. It provides you a very rough idea of what is the project "VIRION" about.

adoptive micro potentiate ally lines prognostic back lytic viruses successes network genetically tumors modified genes patient suppressive cancer variety suppression tool lymphocytes treatment hurdle surgery ed fight shown interference tumor relieve checkpoints regime combination anti microenvironment limits cells clinical combining favorable enhanced efficacy elimination expanded infiltration oncolytic vivo sirna infused astonishing superior had immune play adenoviruses modulating antitumor therapy stimulated outcomes competitive lymphocytic rna destroy radiation subsequent reaction internationally stimulation environment virion chemotherapy powerful patients cell models regimens first proven inflammation immunotherapy direct oncology act trials therapeutic ex cancers techniques virotherapy therapies

Project "VIRION" data sheet

The following table provides information about the project.

Coordinator	STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.virion-consortium.eu
Total cost	1˙304˙413 €
EC max contribution	1˙304˙413 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2014
Funding Scheme	MSCA-ITN-EID
Starting year	2015
Duration (year-month-day)	from 2015-10-01 to 2019-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STICHTING VUMC STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	510˙748.00
2	TILT BIOTHERAPEUTICS OY TILT BIOTHERAPEUTICS OY Organization address address: HAARTMANINKATU 3 C city: HELSINKI postcode: 290 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (HELSINKI)	participant	538˙290.00
3	ORCA Therapeutics BV ORCA Therapeutics BV Organization address address: Jonkerbosplein 52 city: Nijmegen postcode: 6534AB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Nijmegen)	participant	255˙374.00
4	STICHTING VU STICHTING VU Organization address address: DE BOELELAAN 1105 city: AMSTERDAM postcode: 1081 HV website: www.vu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	0.00
5	Adiutide Pharmaceuticals GmbH Adiutide Pharmaceuticals GmbH Organization address address: Zum Talblick 31 city: Glashuetten postcode: 61479 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Glashuetten)	partner	0.00
6	Diamond Biopharm Limited Diamond Biopharm Limited Organization address address: n.a. city: Sawbridgeworth postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (Sawbridgeworth)	partner	0.00
7	Hyphen Projects BV Hyphen Projects BV Organization address address: n.a. city: Hilversum postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Hilversum)	partner	0.00
8	Netherlands society of gene and cell therapy Netherlands society of gene and cell therapy Organization address address: n.a. city: Amsterdam postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Amsterdam)	partner	0.00
9	Quintess Consultancy BV Quintess Consultancy BV Organization address address: n.a. city: Schiedam postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Schiedam)	partner	0.00

Map

Project objective

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques.

Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses.

However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

Deliverables

List of deliverables.
Doctorate	Other	2020-01-14 16:23:20
Presentation	Other	2019-10-15 13:18:34
Supervisory board of the network	Other	2019-06-12 11:55:37
Recruitment	Other	2019-06-12 11:55:37
Public website	Websites, patent fillings, videos etc.	2019-06-12 11:55:37
Communication	Websites, patent fillings, videos etc.	2019-06-12 11:55:37

Take a look to the deliverables list in detail: detailed list of VIRION deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2016	Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri TÃ¤htinen, VÃctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus VÃ¤hÃ¤-Koskela, Anna Kanerva, Akseli Hemminki Corrigendum to â€œAdenoviral Delivery of Tumor Necrosis Factor-Î± and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanomaâ€ published pages: 2033, ISSN: 1525-0016, DOI: 10.1038/mt.2016.196	Molecular Therapy 24/11	2019-10-29
2018	Riikka Havunen, JoÃ£o M. Santos, Suvi Sorsa, Tommi Rantapero, Dave Lumen, Mikko Siurala, Anu J. Airaksinen, Victor Cervera-Carrascon, Siri TÃ¤htinen, Anna Kanerva, Akseli Hemminki Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus published pages: 109-121, ISSN: 2372-7705, DOI: 10.1016/j.omto.2018.10.005	Molecular Therapy - Oncolytics 11	2019-10-29
2018	Tereza Brachtlova, Victor van Beusechem Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens published pages: 228, ISSN: 2073-4409, DOI: 10.3390/cells7120228	Cells 7/12	2019-10-29
2019	Camilla HeiniÃ¶, Suvi Sorsa, Mikko Siurala, Susanna GrÃ¶nberg-VÃ¤hÃ¤-Koskela, Riikka Havunen, Elina Haavisto, Anniina Koski, Otto Hemminki, Sadia Zafar, VÃctor Cervera-Carrascon, Eleonora Munaro, Anna Kanerva, Akseli Hemminki Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs published pages: 740-752, ISSN: 1043-0342, DOI: 10.1089/hum.2018.240	Human Gene Therapy 30/6	2019-10-29
2016	Mikko Siurala, Riikka Havunen, Dipongkor Saha, Dave Lumen, Anu J. Airaksinen, Siri TÃ¤htinen, VÃctor Cervera-Carrascon, Simona Bramante, Suvi Parviainen, Markus VÃ¤hÃ¤-Koskela, Anna Kanerva, Akseli Hemminki Adenoviral Delivery of Tumor Necrosis Factor-Î± and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma published pages: 1435-1443, ISSN: 1525-0016, DOI: 10.1038/mt.2016.137	Molecular Therapy 24/8	2019-10-29
2019	Victor Cervera-Carrascon, Riikka Havunen, Akseli Hemminki Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. published pages: 443-455, ISSN: 1471-2598, DOI: 10.1080/14712598.2019.1595582	Expert Opinion on Biological Therapy 19/5	2019-10-29
2017	Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna GrÃ¶nberg-VÃ¤hÃ¤-Koskela, Michael Behr, Siri TÃ¤htinen, JoÃ£o Manuel Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva, Akseli Hemminki Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy published pages: 77-86, ISSN: 2372-7705, DOI: 10.1016/j.omto.2016.12.004	Molecular Therapy - Oncolytics 4	2019-10-29
2018	Sadia Zafar, Suvi Sorsa, Mikko Siurala, Otto Hemminki, Riikka Havunen, Victor Cervera-Carrascon, JoÃ£o Manuel Santos, Hongjie Wang, Andre Lieber, Tanja De Gruijl, Anna Kanerva, Akseli Hemminki CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy published pages: e1490856, ISSN: 2162-402X, DOI: 10.1080/2162402x.2018.1490856	OncoImmunology 7/10	2019-10-29
2018	JoÃ£o Manuel Santos, VÃctor Cervera-Carrascon, Riikka Havunen, Sadia Zafar, Mikko Siurala, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy published pages: 2243-2254, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2018.06.001	Molecular Therapy 26/9	2019-10-29
2017	Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri TÃ¤htinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma published pages: e1319028, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1319028	OncoImmunology 6/9	2019-10-29
2018	V. Cervera-Carrascon, M. Siurala, J. M. Santos, R. Havunen, S. TÃ¤htinen, P. Karell, S. Sorsa, A. Kanerva, A. Hemminki TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade published pages: e1412902, ISSN: 2162-402X, DOI: 10.1080/2162402x.2017.1412902	OncoImmunology 7/5	2019-10-29
2017	Joao Manuel Santos, Riikka Havunen, Mikko Siurala, VÃctor Cervera-Carrascon, Siri TÃ¤htinen, Suvi Sorsa, Marjukka Anttila, Pauliina Karell, Anna Kanerva, Akseli Hemminki Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy published pages: 1458-1468, ISSN: 0020-7136, DOI: 10.1002/ijc.30839	International Journal of Cancer 141/7	2019-06-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIRION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIRION" are provided by the European Opendata Portal: CORDIS opendata.